Financial Performance - The company's revenue for Q3 2022 was ¥219,260,922.75, representing a year-on-year increase of 162.30%[6] - The net profit attributable to shareholders for Q3 2022 was -¥199,094,007.06, with a year-to-date net profit of -¥688,219,233.92[6] - Total operating revenue for the first three quarters of 2022 reached ¥569,635,902.97, a significant increase from ¥114,506,776.26 in the same period of 2021, representing a growth of approximately 397%[21] - The net loss for the third quarter of 2022 was ¥688,219,233.92, slightly improved from a net loss of ¥688,259,394.55 in the same quarter of the previous year[22] - The total comprehensive loss for the third quarter of 2022 was ¥680,108,752.02, compared to a loss of ¥688,616,249.38 in the prior year[22] - Basic and diluted earnings per share for the third quarter of 2022 were both -¥1.32, compared to -¥1.41 in the same quarter of 2021[22] Research and Development - Research and development expenses totaled ¥212,869,547.05 for Q3 2022, accounting for 97.09% of revenue, a decrease of 139.80 percentage points compared to the previous year[7] - The company has seen a substantial increase in R&D spending, which is expected to continue as it develops new products and technologies[10] - Research and development expenses for the first three quarters of 2022 were ¥662,541,383.59, up from ¥524,624,528.96 in 2021, reflecting a growth of approximately 26%[21] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥5,971,303,165.55, an increase of 43.57% compared to the end of the previous year[7] - The equity attributable to shareholders at the end of Q3 2022 was ¥5,267,753,628.11, reflecting a 52.85% increase year-on-year[7] - Current assets reached RMB 3,559,051,782.58, up from RMB 2,299,951,998.84 year-over-year[19] - Cash and cash equivalents were RMB 2,034,818,774.76, compared to RMB 1,835,498,496.42 at the end of 2021, reflecting a growth of approximately 10.9%[19] - Inventory increased to RMB 442,285,036.79 from RMB 280,314,179.90, representing a growth of about 57.8%[19] - The company reported accounts receivable of RMB 142,552,160.15, a significant increase from RMB 2,311,600.59 in the previous year[19] - The company has no short-term borrowings reported as of September 30, 2022[19] - The total liabilities include accounts payable of RMB 63,812,763.95, which increased from RMB 36,521,319.13[19] - The company's total liabilities as of the third quarter of 2022 were ¥703,549,537.44, a decrease from ¥712,787,425.02 in the previous quarter[20] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥1,080,292,854.28, indicating increased cash outflows primarily due to higher material costs and personnel expenses[7] - The net cash flow from operating activities for the first three quarters of 2022 was -1,080,292,854.28 RMB, compared to -719,808,495.41 RMB in the same period of 2021, indicating a decline of approximately 50.1%[23] - Total cash inflow from investment activities was 685,653,675.14 RMB, while cash outflow was 1,845,377,906.56 RMB, resulting in a net cash flow from investment activities of -1,159,724,231.42 RMB, a significant increase in losses compared to -470,640,588.01 RMB in 2021[23] - The net cash flow from financing activities was 2,438,024,300.14 RMB, a recovery from a negative cash flow of -569,256,534.70 RMB in the same period last year[23] - The ending balance of cash and cash equivalents increased to 1,967,108,319.61 RMB, up from 1,003,253,752.77 RMB in the previous year, reflecting a growth of approximately 96.0%[25] Shareholder Information - The company has a total of 6,764 common shareholders as of the report date[12] - The top shareholder, HKSCC NOMINEES LIMITED, holds 189,566,228 shares, representing 34.83% of total shares[12]
荣昌生物(09995) - 2022 Q3 - 季度财报